Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marcello Borzatta

Vascular Surgery Crestview, FL Medical Doctor

NPI 1154368181 CMS profile 187802

2260 S Ferdon Blvd, Crestview, FL 32536

Open in the dashboard

General payments

$8,148

100 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marcello Borzatta of Crestview, FL is reported in the CMS Open Payments database as having received $8,148 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,791 12
2024 General $499 6
2023 General $2,286 17
2022 General $875 23
2021 General $439 12
2020 General $1,605 16
2019 General $654 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marcello Borzatta
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Marcello Borzatta were reported at $1,791. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Marcello Borzatta Vascular Surgery median Middle half National median
2019 $654 $796 $226–$2,363 $163
2020 $1,605 $348 $118–$1,110 $114
2021 $439 $471 $158–$1,421 $132
2022 $875 $725 $222–$2,183 $149
2023 $2,286 $836 $257–$2,440 $160
2024 $499 $909 $252–$2,619 $164
2025 $1,791 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $3,816 16 payments
  2. W. L. Gore & Associates, Inc. $1,798 14 payments
  3. AngioDynamics, Inc. $1,071 18 payments
  4. Bard Peripheral Vascular, Inc. $612 14 payments
  5. Cardiovascular Systems Inc. $249 10 payments
  6. Veryan Medical Incorporated $119 2 payments
  7. Medtronic, Inc. $117 4 payments
  8. Maquet Cardiovascular U.S. Sales, L.L.C. $97 6 payments
  9. Inari Medical, Inc. $84 5 payments
  10. Abbott Laboratories $47 2 payments
  11. Other $136 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,442 95 payments
  2. Travel and Lodging $2,706 5 payments
Products named General payments · program years 2019–2025
  1. Indigo System $3,791 14 payments
  2. AURYON LASER SYSTEM 100-120 VAC $981 17 payments
  3. VIABAHN Endoprosthesis $684 4 payments
  4. TAG Thoracic Endoprosthesis $455 2 payments
  5. VIABAHN VBX Balloon Expandable Endoprosthesis $337 2 payments
  6. Diamondback Peripheral $232 9 payments
  7. GORE VIABAHN Endoprosthesis $129 2 payments
  8. VIABAHN Endoprosthesis with PROPATEN Bioactive Surface $122 2 payments
  9. BioMimics 3D Vascular Stent System $119 2 payments
  10. ULTRASCORE $113 5 payments
  11. Other $1,005 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

119

Median for Vascular Surgery: 122

Drug cost

$30,798

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 34 $19,358
Xarelto Rivaroxaban Brand 14 $10,866
Clopidogrel Clopidogrel Bisulfate Brand 71 $574

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$2,693,209

Medicare's payments for the services billed

Medicare patients

266

Average age 76

Services billed

2,325

121 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Arthritis 56%
Chronic kidney disease 53%
Diabetes 49%
Heart failure 45%
COPD 45%
Atrial fibrillation 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record